Redeye comments on FluoGuide’s Q4 2024 report. The company is approaching the interim readout of its phase II trial in HNC (H2 2025e), which we judge could pave the way for initiating pivotal trials. Further, we judge Fluoguide’s business development prospects remain healthy. We update our estimates and valuation.
LÄS MER
